Characterization and stabilization of recombinant human protein pentraxin (rhPTX-2)

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 827-841

  Liu, Jing ^a,c,d   Blasie, Cheryl A ^b,c,d   Shi, Shuai ^a,c,d   Joshi, Sangeeta B ^a,c,d   Middaugh, C Russell ^a,c,d   Volkin, David B ^a,c,d  

^a UNIVERSITY OF KANSAS   (United States)

^b Promedior Inc   (United States)

^c SEATTLE GENETICS INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biopharmaceuticals characterization; Biophysical; Formulation; Pentraxin; Protein aggregation; Serum amyloid protein; Spectroscopy; Stabilization

Indexed keywords

AMINO ACID; CITRIC ACID; DISACCHARIDE; MONOMER; PENTRAXIN; PENTRAXIN 2; SUGAR ALCOHOL; UNCLASSIFIED DRUG;

ARTICLE; BIOPHYSICS; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DECOMPOSITION; DRUG STABILITY; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PH; PREFORMULATION; PROTEIN AGGREGATION; STRUCTURE ANALYSIS; TEMPERATURE; ULTRACENTRIFUGATION;

EID: 84878146591     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23360     Document Type: Article

References (34)

1. Garlanda C, Bottazzi B, Bastone A, Mantovani A. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23:337-366.
2. Mantovani A, Garlanda C, Doni A, Bottazzi B. 2008. Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. J Clin Immunol 28(1):1-13.
3. Gewurz H, Zhang XH, Lint TF. 1995. Structure and function of the pentraxins. Curr Opin Immunol 7(1):54-64.
4. Steel DM, Whitehead AS. 1994. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15(2):81-88.
5. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. 1997. Amyloid P component. A critical review. Amyloid 4:274-295.
6. Castano AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T, Singh A, Li S, Lupher ML, Jr., Duffield JS. 2009. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 1(5):5ra13.
7. Hohenester E, Hutchinson WL, Pepys MB, Wood SP. 1997. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. J Mol Biol 269(4):570-578.
8. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP. 1994. Structure of pentameric human serum amyloid P component. Nature 367(6461):338-345.
9. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. 2008. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 456(7224):989-992.
10. Pilling D, Buckley CD, Salmon M, Gomer RH. 2003. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 171(10):5537-5546.
11. Pilling D, Tucker NM, Gomer RH. 2006. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 79(6):1242-1251.
12. Duffield J, Lupher MJ. 2010. PRM-151 (recombinant human serum amyloid P/Pentraxin 2) for the treatment of fibrosis. Drug News Perspect 23(5):305-315.
13. Promedior, Inc. Jul. 23, 2009. Promedior initiates phase 1 clinical trial of PRM-151, a novel compound for the treatment of fibrotic diseases and tissue remodeling [news release]. Accessed, at: http://www.promedior.com/news/index.html.
14. Promedior, Inc. Sept. 7, 2010. Promedior announces initiation of phase 2a clinical study of anti-fibrotic therapeutic, PRM-151, in the prevention of post-surgical scarring in glaucoma patients [news release]. Accessed, at: http://www.promedior.com/news/index.html.
15. Promedior, Inc. Feb. 10, 2011. Promedior initiates clinical study of anti-fibrotic therapeutic, PRM-151, in patients with idiopathic pulmonary fibrosis (IPF) [news release]. Accessed, at: http://www.promedior.com/news/index.html.
16. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB. 2012. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci 101(6):1969-1984.
17. Joshi SB, Bhambhani A, Zeng Y, Middaugh CR. 2010. An empirical phase diagram/high throughput screening approach to the characterization and formulation of biopharmaceuticals. In Formulation and process development strategies for manufacturing biopharmaceuticals; Jameel F, Hershenson S, Eds. 1st ed. Hoboken, New Jersey: John Wiley & Sons publication, pp 173-204.
18. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. 2011. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100(10):4171-4197.
19. Gabellieri E, Strambini GB. 2006. ANS fluorescence detects widespread perturbations of protein tertiary structure in ice. Biophys J 90(9):3239-3245.
20. Hawe A, Friess W, Sutter M, Jiskoot W. 2008. Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal Biochem 378(2):115-122.
21. Semisotnov GV, Rodionova NA, Razgulyaev OI, Uversky VN, Gripas AF, Gilmanshin RI. 1991. Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 31(1):119-128.
22. Liu J, Andya JD, Shire SJ. 2006. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J 8(3):E580-E589.
23. Lebowitz J, Lewis MS, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11(9):2067-2079.
24. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB. 2010. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99(6):2582-2597.
25. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G. 2010. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 99(5):2200-2208.
26. Bee JS, Randolph TW, Carpenter JF, Bishop SM, Dimitrova MN 2011. Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci 100(10): 4158-4170.
27. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185(2):129-188.
28. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27(4):544-575.
29. Cheng W, Joshi SB, He F, Brems DN, He B, Kerwin BA, Volkin DB, Middaugh CR. 2012. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: Conformational stability and kinetic aggregation measurements. J Pharm Sci 101(5):1701-1720.
30. Wang W, Roberts C. 2010. Aggregation of therapeutic proteins. 1st ed. Hoboken, New Jersey: John Wiley & Sons, Inc.
31. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. 2011. Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63(13):1118-1159.
32. Timasheff SN. 2002. Protein hydration, thermodynamic binding, and preferential hydration. Biochemistry 41(46):13473-13482.
33. Timasheff SN. 2002. Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components. Proc Natl Acad Sci U S A 99(15):9721-9726.
34. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. 1997. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci U S A 94(22):11917-11922.